The success of locoregional, low-dose recombinant interleukin-2 therapy in tumor-bearing mice is dependent on the time of rIL-2 administration

Journal of Experimental Therapeutics and Oncology

Volumn 1, Issue 4, 1996, Pages 231-236

  Everse, Linda A ^a   Bernsen, Monique R ^a   Dullens, Hub F J ^b   Den Otter, Willem ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cancer; Interleukin 2; Scheduling; Therapy

Indexed keywords

INTERLEUKIN 2; RECOMBINANT PROTEIN;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CULTURE MEDIUM; DBA MOUSE; DRUG EFFECT; HUMAN; IMMUNOLOGY; LYMPHOMA; MOUSE; PATHOLOGY; PHYSIOLOGY; TIME; XENOGRAFT;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CULTURE MEDIA; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-2; LYMPHOMA; MICE; MICE, INBRED DBA; NEOPLASM TRANSPLANTATION; RECOMBINANT PROTEINS; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 0030177334     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Rosenberg SA, Lofze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485-1492, 1985.
2. Albertini MR, Sosman JA, Hank JA, et al. The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2. Cancer 66: 2457-2464, 1990.
3. Clamon G, Herndon J, Perry MC, et al. Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B. J Natl Cancer Inst 85: 316-320, 1993.
4. Dillman RO, Church C, Oldham RK, West WH, Schwartzberg L, Birch R. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience. Cancer 71: 2358-2370, 1993.
5. Den Otter W, Hill FWG, Klein WR, et al. Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up. Cancer Immunol Immunother 41: 10-14, 1995.
6. Mattijssen V, De Mulder PHM, De Graeff A, et al. Intratumoral PEG-interleukin-2 therapy in patients with locoregionally recurrent head and neck squamous-cell carcinoma. Ann Oncol 5: 957-960, 1994.
7. Ravaud A, Negrier S, Cany L, et al. Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma. Br J Cancer 69: 1111-1114, 1994.
8. Sone S, Ogura T. Local interleukin-2 therapy for cancer, and its effector induction mechanisms. Oncology 51: 170-176, 1994.
9. Yang JC, Topalian SL, Parkinson D, et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 12: 1572-1576, 1994.
10. Maas RA, Dullens HFJ, De Jong WH, Den Otter W. Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2. Cancer Res 49: 7037-7040, 1989.
11. Maas RA, Dullens HFJ, Den Otter W. Mechanisms of tumor regression induced by low doses of interleukin-2. In Vivo 5: 637-641, 1991.
12. Ferrara P, Pecceu F, Marchese E, Vita N, Roskam W, Lupker J. Characterization of recombinant glycosylated human interleukin 2 produced by a recombinant plasmid transformed CHO cell line. FEBS Letters 226: 47-52, 1987.
13. Bubenik J, Indrova M. Cancer immunotherapy using local interleukin 2 administration. Immunol Lett 16: 305-309, 1987.
14. Ottow RT, Steller EP, Sugarbaker PH, Wesley RA, Rosenberg SA. Immunotherapy of intraperitoneal cancer with interleukin 2 and lymphokine-activated killer cells reduces tumor load and prolongs survival in murine models. Cell Immunol 104: 366-376, 1987.
15. Vaage J. Peri-tumor interleukin-2 causes systemic therapeutic effect via interferon-gamma induction. Int J Cancer 49: 598-600, 1991.
16. Den Otter W, Maas RA, Koten JW, et al. Effective immunotherapy with local low doses of interleukin-2. In Vivo 5: 561-565, 1991.
17. Dullens HFJ, Hilgers J, Spit BJ, et al. Staging, growth properties and metastatic behaviour of a transplantable murine T-cell lymphoma. Int J Tissue React 4: 15-25, 1982.
18. Den Otter W, Hill FWG, Klein WR, et al. Low doses of interleukin-2 can cure large bovine ocular squamous cell carcinoma. Anticancer Res 13: 2453-2455, 1993.